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Abstract
Background: Trachoma, a preventable blinding eye disease, is initiated by ocular infection with Chlamydia trachomatis
(Ct). We previously showed that microRNAs (miR) -147b and miR-1285 were up-regulated in inflammatory
trachomatous scarring. During the initial stage of disease, follicular trachoma with current Ct infection, the
differential expression of miR has not yet been investigated.
Methods: Conjunctival samples were collected from 163 children aged 1–9 years old living in a trachoma-endemic
region of Guinea Bissau, West Africa. Small RNA sequencing (RNAseq) was carried out on samples from five children
with follicular trachoma and current Ct infection and five children with healthy conjunctivae and no Ct infection.
Small RNAseq was also carried out on human epithelial cell lines infected with ocular Ct strains A2497 and
isogenic plasmid-free A2497 in vitro. Results were validated by quantitative PCR (qPCR) in 163 clinical samples.
Results: Differential expression of RNAseq data identified 12 miR with changes in relative expression during
follicular trachoma, of which 9 were confirmed as differentially expressed by qPCR (miR-155, miR-150, miR-142,
miR-181b, miR-181a, miR-342, miR-132, miR-4728 and miR-184). MiR-155 and miR-184 expression had a direct
relationship with the degree of clinical inflammation. MiR-155 was up-regulated (OR = 2.533 ((95 % CI = 1.291–4.971);
P = 0.0069) and miR-184 was down-regulated (OR = 0.416 ((95 % CI = 0.300–0.578); P = 1.61*10−7) as the severity
of clinical inflammation increased. Differential miR expression was not detected in HEp-2 or HCjE epithelial
cells 48 h post infection with Ct in vitro. HCjE cells, a conjunctival epithelial cell line, had a markedly different
miR background expression compared to HEp-2 cells.
Conclusions: In follicular trachoma, expression of miR-155 and miR-184 is correlated with the severity of
inflammation. This likely reflects host regulation of the immune response and a prolonged period of wound
healing following the clearance of Ct. Prolonged healing may be associated with subsequent development of
scarring trachoma.
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Background
Trachoma is the leading infectious cause of blindness
worldwide and is initiated by infection of the conjunc-
tival epithelium with the obligate intracellular bacterium
Chlamydia trachomatis (Ct). In trachoma-endemic areas
children suffer repeated episodes of infection and the
effects of the associated immune response, which is
characterized by a follicular conjunctivitis. In some indi-
viduals this triggers a chronic inflammatory response,
causing scarring of the eyelid over the course of the life-
time of the individual, often in the absence of detectable
Ct infection [1]. Conjunctival fibrosis causes entropion
(in-turning of the lid margin) and subsequent trichiasis,
the inward turning of eyelashes, which scratch the cornea
causing mechanical damage leading to blinding corneal
opacification in a proportion of cases. The mechanisms of
fibrotic progression in the absence of Ct infection and the
reason why only some individuals in trachoma-endemic
communities develop scarring despite similar exposure to
infection are unknown.
Trachoma is endemic in 51 countries and is associated
with visual impairment in 2.2 million people worldwide
(of whom 1.2 million are irreversibly blind) [2]. The World
Health Organization (WHO) strategy for the elimination
of trachoma (“SAFE”) consists of mass distribution of anti-
biotics (MDA) to communities to treat infection, surgery
for trichiasis, promotion of facial hygiene and environ-
mental and sanitation improvements such as provision of
latrines to reduce transmission [3].
Whilst MDA is generally effective, there are concerns
regarding its efficacy in hyper-endemic settings such
as Ethiopia, where trachoma prevalence remains high
despite >5 years of biannual MDA in some districts
[4]. High recurrence rates of trichiasis following lid
margin rotation surgery [5] and the presence of follicular
trachoma and incident scarring in populations where Ct
infection prevalence has been controlled [1, 6] are also of
concern. In order to develop an anti-Ct vaccine that
invokes a protective immune response and to design
therapeutic treatments to halt progressive scarring, a bet-
ter understanding of the immunopathology of chlamydial
disease is required.
Experimental conjunctival Ct infection of human vol-
unteers found the incubation period to be between 2
and 19 days post inoculation [7, 8], whilst mathematical
models based on data from disease and infection studies
in trachoma-endemic communities estimated this period
as around 17 days [9]. Although some infected individuals
remain asymptomatic, many will develop clinical signs of
follicular trachoma, such as lymphoid follicles and papillary
inflammation. The median duration of follicular trachoma
has been observed to decrease with age; from 13.2 weeks
in 0–4 year olds to 1.7 weeks in individuals of 15 years
or more [10]. The cumulative incidence rate of follicular
trachoma is also reduced threefold with age, implying
that some degree of protective immunity is acquired [10].
There is a lag time between the clearance of infection and
the disappearance of clinical signs of follicular trachoma
on both an individual (median time of five weeks [9]) and
population level [11, 12].
MicroRNA (miR) are small single-stranded RNA spe-
cies that regulate gene expression post-transcriptionally.
MiR can have profound effects on health and disease
and there are many examples in which abnormal expres-
sion of a single [13] or small number [14] of miR are
associated with disease. We have previously found that
miR-147b and miR-1285 are up-regulated in adult cases
of scarring and inflammatory trachoma [15]. Others have
investigated the miR response to Ct and C. muridarum
(Cm) in the murine genital tract [16–18], but the miR re-
sponse to Ct in human disease has not yet been reported.
In this study we examine the miR response in clinical
cases of follicular trachoma with Ct infection and during
Ct infection of cultured human epithelial cells.
Methods
Ethics, consent and permissions
The study was conducted in accordance with the dec-
laration of Helsinki and was approved by the Ethics
committee of the London School of Hygiene and Tropical
Medicine (reference: 6433) and the Comité Nacional de
Ética em Saúde of Guinea Bissau (reference: 012/CNES/
INASA/2013). Written informed consent was obtained
from a parent or guardian before participants were en-
rolled in the study.
Clinical sample collection
Prospective samples were collected from children aged
from 1 to 9 years residing on seven islands of the Bijagos
Archipelago, Guinea Bissau, 6 islands of which were
trachoma treatment naïve at the time of sample collection.
Children were screened for clinical signs of trachoma by a
trained clinician using the WHO 1981 FPC scoring system
[19]. Individuals presenting with follicular trachoma scores
of “F2” or “F3” were roughly equivalent to “Trachomatous
Inflammation − Follicular (TF)” in the WHO simplified
trachoma grading system [20] and are hereafter referred
to as TF cases. Individuals with pronounced papillary
hypertrophy and diffuse infiltration (score “P3“) were
equivalent to “Trachomatous Inflammation − Intense (TI)”
in the WHO simplified grading system. Individuals with
no clinical signs of follicles (F0), papillary hypertrophy
(P0) or conjunctival scarring (C0) were classed as normal
healthy controls (N). A case was defined as a child with
TF in both eyes irrespective of P score. A healthy control
was enrolled for each TF case where a case was defined as
an individual with an F-score ≥ F2. Cases and controls
were matched by age, gender and village.
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Two conjunctival samples were taken from the left
upper tarsal conjunctiva of each participant with Dacron
swabs (Puritan, Guilford, ME, USA) using standard
methodology [21, 22]. Swabs were stored in RNAlater
(Ambion, Life technologies, Carlsbad CA, USA) and kept
in a cold chain in the field before subsequent storage
at −80 °C. The two swabs from each individual were
pooled for RNA and DNA extraction.
In vitro culture and Ct infection of human epithelial cell
lines
Human epithelial type 2 (HEp-2) cells were cultured in
Minimum Essential Medium (MEM) (Gibco, Life Tech-
nologies) supplemented with 1 % gentamicin (Gibco),
10 % fetal bovine serum (FBS) (Gibco), and 1 % L-glu-
tamine (Gibco). For the in vitro experiments, cells were
seeded in 12 well plates at 3×105 cells per well in MEM.
An immortalized human conjunctival epithelial cell line
(HCjE) was cultured in Keratinocyte serum free medium
(K-sfm) (Gibco) supplemented with 25 μg/ml bovine pitu-
itary extract (Gibco), 0.2 ng/ml epidermal growth factor
(Gibco), 0.4 mM CaCl2 (Sigma, St. Louis, MO, USA) and
5 % gentamicin and incubated at 37 °C with 5 % atmos-
pheric CO2. For experiments, HCjE cells were seeded in
12 well plates at 3×105 cells per well in 1:1 K-sfm [with
supplements]: Dulbecco’s Modified Eagle Medium: Nutri-
ent Mixture F12 (DMEM/F12) [with 10 % FBS, 1 % genta-
micin and 1 % L-glutamine] (Gibco) and were switched to
DMEM/F12 [with supplements] upon infection 24 h later.
HEp-2 and HCjE cells were infected with 3 different
ocular-derived serovar A Ct strains: A2497 (described in
[23]), its plasmid cured counterpart (A2497P-) [24] and
A/HAR-13 [23]. Cells were infected 24 h after seeding at
a multiplicity of infection (MOI) of 1 and without the
addition of cycloheximide. Ct cultures and mock-infected
cells were centrifuged at 1800 r.p.m. for 1 hr to facilitate
infection and were then incubated at 37 °C in 5 % CO2.
Six replicates were carried out for each biological condi-
tion. At 48 h post-infection (hpi), media was removed and
cells were washed in 1X phosphate-buffered saline (PBS)
(Sigma). Productive infection was measured by digital
PCR, as detailed below and through visualization of inclu-
sions using confocal microscopy.
Microscopy
Cell monolayers were seeded on glass coverslips and at
48 hpi media was removed and cells were washed in 1X
PBS. 200 μl ice cold 100 % methanol was added to each
well for 10 min. In order to block the cells, they were
washed in 1X PBS and incubated in 200 μl 1 % w/v bo-
vine serum albumin (BSA)/PBS for 30 min at room
temperature. Cells were then incubated for 30 min in the
dark with 100 μl of a 1 % v/v solution of anti-Chlamydia
trachomatis MOMP antibody (FITC) (ab30951, Abcam,
Cambridge, UK) in 1 % w/v BSA/PBS. Cells were washed
3x in 1X PBS for 5 min each wash. DAPI dilactate (1 μg/
ml (Sigma)) was added for 5 min. Cells were washed 3x in
1X PBS. Slides were mounted with coverslips and viewed
on a Zeiss LSM510 confocal microscope at 40X magnifi-
cation. Images were captured using the tile function in
Volocity, V5.5.1 (PerkinElmer, Waltham, MA, USA).
Nucleic acid extraction
For in vitro cultures 300 μl lysis buffer (Norgen Biotek,
Thorold, ON, Canada) was added to each well and cells
were harvested by scraping. Ocular swabs were thawed
and added to a 1.5 ml microcentrifuge tube containing
300 μl lysis buffer (Norgen Biotek) and were vortexed
for one minute. Total RNA and DNA were extracted from
both sample types using the Norgen RNA and DNA puri-
fication kit according to the manufacturers instructions.
Total RNA was quantified using Qubit® fluorometric
quantitation (Life Technologies) and quality was assessed
using an Agilent RNA 6000 pico kit on a 2100 Bioanalyzer
instrument (Agilent technologies, Santa Clara, CA, USA).
Ct infection load by droplet digital PCR
A droplet-digital PCR assay was carried out to diagnose
Ct infection, as described previously [25, 26] with the
following modifications. Forward and reverse primers
were used at 0.9 μM and probes were used 0.2 μM. Eight
microlitres of sample DNA was added to each reaction.
For clinical samples, an initial diagnostic assay detecting
Ct plasmid and human RPP30 endogenous control was
carried out on all samples. Ct omcB and plasmid DNA
was then quantified in positive samples to determine Ct
load. This assay was also performed on in vitro samples
to quantitate Ct omcB load and to check that there was
no cross contamination of plasmid competent Ct in
plasmid-free Ct cultures. Primer and probe sequences
are described elsewhere [26]. Thermal cycling conditions
were as follows: 95 °C hold for 10 min, followed by 40 cy-
cles of 95 °C for 10 s and 60 °C for 20 s with a final hold
of 98 °C for 12 min. ddPCR was performed on a Bio-Rad
QX100 Instrument and data were collected using Quanta-
life software (Bio-Rad, Hercules, CA, USA). Copy number
was calculated in R using previously published scripts [25].
Small RNA sequencing
Small RNA libraries were prepared using TruSeq® Small
RNA sample preparation kit (Illumina, San Diego, CA,
USA), carried out following the manufacturer’s instructions.
In vitro-derived samples chosen for sequencing had an
RNA Integrity number (RIN) > 8 and a concentration of at
least 0.2 μg/μl total RNA. Sample concentrations were nor-
malized prior to small RNA library preparation. Clinical
samples chosen for sequencing had an RIN > 8 and were
normalized to the sample with the lowest concentration
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(24 ng/μl). Libraries were sequenced on a MiSeq desktop
sequencer (Illumina). Sequencing reads were analyzed
as described previously [27] with an amendment such
that only reads with a Phred33 score of 30 or more
were retained. Differential analysis was performed on
read count data using two analysis packages in R, DESeq
(which is believed to be conservative) and EdgeR [28–30].
In both methods miR with an average read count across
all samples of less than five were excluded from each ana-
lysis. P values were adjusted for false discovery rate (FDR)
using the Benjamini-Hochberg procedure [31]. Raw and
processed sequencing data along with processing work-
flows are deposited in the NCBI GEO public database
(GSE69837).
MiR qPCR and statistical analysis
Total RNA was reverse transcribed and expression levels
were quantified by quantitative PCR (qPCR) using the
MiScript system (Qiagen, Venlo, Limburg, Netherlands)
as described previously [15]. Thermal cycling conditions
were 95 °C for 15 min followed by 40 cycles of 94 °C for
15 s, 55 °C 30 s, and 70 °C 30 s. Data was collected at
70 °C. Cycle thresholds were calculated using an auto-
matic baseline and a threshold of 0.1 for all clinical and
in vitro samples. Differential expression analysis of cycle
threshold values was carried out as described previously
[15]. FDR adjusted P values were calculated using the
Benjamini-Hochberg procedure.
The relationship between conjunctival papillary inflam-
mation (P) score and the expression of miR that were sig-
nificantly differentially expressed in TF versus N by qPCR
was examined using ordinal logistic regression models in
R (MASS package [32]). Clinical scores P2 and P3 were
combined due to the low number of P3 scores (n = 6) and
individuals were classified as P0 (n = 84), P1 (n = 53) and
P2/P3 (n = 29) as an ordinal response variable. Age, gender
and the natural logarithm of Ct omcB load were included
in the model and miR expression levels (40-delta cycle
threshold (ΔCT) value) were included as independent
variables. This value (40-ΔCT) was used so that an odds
ratio (OR) >1 would reflect an up-regulation of miR ex-
pression and vice versa. Univariable ordinal regression was
performed for each miR and miR with a P value < 0.05
were included in the final multivariate model. F and P
scores were tested for collinearity: A high kappa score and
a covariance matrix value near zero indicates collinearity
(0 = perfect colinearity, 1 = no colinearity). Post-hoc ana-
lyses were carried out on miR with a P value <0.05 in the
multivariate model. Kruskal-Wallis and post-hoc Kruskal
Nemenyi tests (Tukey method) were carried out in R
using the PMCMR package [33] to detect pairwise differ-
ences between miR expression and collapsed papillary
inflammation score. Kruskal Nemenyi test P values were
adjusted using the Benjamini-Hochberg procedure.
Results
In vitro infections
HEp-2 and HCjE epithelial cell lines were infected in
vitro with 3 different serovar A ocular strains of Ct; A/
HAR-13, A2497 and plasmid-cured A2497. In HEp-2
cells, virulent A2497 plasmid-competent Ct had the
highest mean genome copy number at 48 hpi, which
was slightly higher than that of isogenic plasmid-free
A2497 (A2497P-) (Fig. 1). A/HAR-13 growth was consid-
erably less efficient in these experiments. All 3 strains were
substantially less productive in HCjE cells compared to
HEp-2 cells, as measured by omcB load and microscopy of
inclusions (Fig. 1 and Additional file 1). Due to the low
productivity of A/HAR-13 infection in HEp-2 and HCjE
cells, these samples were not carried forward for small
RNA sequencing. A2497 and A2497P- infected HCjE cells
were sequenced despite the poor infection productivity in
order to contrast small RNA expression between infected
HEp-2 and HCjE cells. Small RNA sequencing was per-
formed on mock-infected, A2497 and A2497P- infected
HEp-2 and HCjE cells.
In HEp-2 cells, 885 miR were detected in mock-infected
cells, 894 miR were detected in A2497 infected cells and
856 miR were detected in A2497P- infected cells. Differen-
tial expression of read count data (miR with an average
read count <5 excluded) was carried out using EdgeR and
DEseq to account for variance in the normalization
method. No miR were differentially expressed (Padj <0.01)
using either method between mock-infected and A2497
infected (377 miR tested) or between mock-infected and
Fig. 1 Yield of three ocular Ct strains in two epithelial cell lines.
Chlamydial genome copy number of three ocular Ct strains
(A2497, A2497p- and A/HAR-13) in HEp-2 and HCjE cells at 48
hpi. Cells were infected at an MOI of 1. Mock-infected cells (−VE)
were treated identically except for the addition of Ct inoculum.
The mean of the total OmcB genome copy number per well of
6 biological replicates is shown
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A2497P- infected (378 miR tested) HEp-2 cells (Additional
file 2). In HCjE cells, 853 miR were detected in mock-
infected cells, 840 miR were detected in A2497 infected
cells and 872 miR were detected in A2497P- infected cells.
No miR were differentially expressed using EdgeR or
DESeq (Padj <0.01) between mock-infected and A2497 in-
fected (357 miR tested) or between mock-infected and
A2497P- infected (372 miR tested) HCjE cells (Additional
file 3).
The miR profile of mock-infected HEp-2 and HCjE cells
was analyzed in order to investigate differences between
these two cell lines. Four hundred and seven miR had an
average read count > 5 in mock-infected HEp-2 and HCjE
cells. Strikingly, DESeq identified 136 out of the 407 miR
tested with an adjusted P value (Padj) < 0.01 and EdgeR
identified 217 miR with Padj < 0.01 (Additional file 4). The
top 3 most differentially expressed miR were members of
the miR-200 family: miR-200b-3p (Padj = 2.11 × 10
−51,
log2FC = 12.3), miR-141-5p (Padj = 1.1 × 10
−32, log2FC =
9.2), and miR-429 (Padj = 1.1 × 10
−32, log2FC =∞), which
were all highly expressed in HCjE cells relative to HEp-2
cells. MiR-429 was detected at an average read count of
379 in mock-infected HCjE cells, whereas it was not
detected at all in HEp-2 cells at the sequencing depth
achieved.
Clinical sample details
Conjunctival swab samples were collected from 81 cases
of TF and 82 clinically normal healthy controls. A sum-
mary of sample phenotypes is shown in Table 1. Five out
of 82 controls and 47/81 cases were positive for Ct DNA
(Chi2 = 55.93, P = 0.0005). The proportion of Ct infected
individuals in each clinical category increases with the
severity of trachomatous inflammation, both follicular and
papillary. Two clinical cases had evidence of conjunctival
scarring; one sample was F2, P1, C1 (Ct positive) and the
other was F3, P2, C2 (Ct negative). The median Ct plasmid
copy number was 1.5 (range 0.4–14.6).
Fifty-one of the 163 clinical samples from which total
RNA was extracted had an RIN > 8. Five of the 51 RIN >
8 samples with the highest RNA concentration that had
TF with current Ct infection were chosen for sequen-
cing. Five control samples (F0,P0,C0) with the highest
RNA concentration and the closest age and sex match
to the 5 TF samples were also sequenced. Total RNA
concentration of all 10 samples was normalized to the
sample with the lowest concentration (24 ng/μl) prior to
library preparation. The mean age of the 5 controls was
6.4 years old and the group consisted of 2 males and 3
females. The mean age of the TF group was 6.2 years old
and the group consisted of 3 males and 2 females. In the
TF group, the sample phenotypes were F2,P1,C0 (n = 2),
F2,P2,C0 (n = 1), F3,P1,C0 (n = 1) and F3,P2,C0 (n = 1).
MiR expression in clinical samples by RNAseq
Deep sequencing of conjunctival small RNA from 10
clinical samples identified 860 miR. MiR-21-5p was the
most highly expressed miR in the conjunctiva of both N
and TF cases (Additional file 5). MiR with an average
read count < 5 in all ten samples were removed. EdgeR
revealed 43 miR (Padj < 0.01, FC > 1.5) and DEseq identi-
fied 12 miR (Padj < 0.01 FC > 1.5 (Additional file 6)) that
were differentially expressed between TF cases and con-
trols. All of the significant miR identified by DEseq were
also significant using EdgeR.
The differential expression of the 12 miR that were
significant in both DESeq and EdgeR analyses was inves-
tigated in 163 clinical samples using qPCR. Two miR
that were previously found to be up-regulated in inflam-
matory trachomatous scarring (miR-147b and miR-1285)
[15] were also tested by qPCR in these samples. Results
were analyzed using the ΔΔCt method [34]. Differential
expression was tested in 3 independent clinical pheno-
type comparisons: TF (n = 81) against normal healthy
controls (N, n = 82), TF with detectable Ct infection (TF
Ct + n = 47) against normal healthy controls without
detectable Ct infection (N Ct-, n = 77), and TF with
Table 1 Trachoma grade and Ct infection load of clinical samples
FPC score Total (% male) Ct positive Ct omcB mediana copies/swab (IQR)b Human RPP30 median copies/swab (IQR)b
Controls (N)
F0P0C0 82 (41 %) 5/82 (6 %) 345 (42–1078) 19290 (13310–25810)
TF cases: Breakdown by follicular score
F2 46 (48 %) 20/46 (43.5 %) 703 (370–25870) 23900 (15670–39440)
F3 35 (31 %) 27/35 (77 %) 6050 (1451–15350) 35250 (19120–43250)
TF cases: Breakdown by papillary hypertrophy score
P1 53 (38 %) 22/53 (71 %) 656 (433–5238) 23280 (15380–34500)
P2 22 (55 %) 19/22 (86 %) 12950 (3638–42880) 37750 (21560–48560)
P3 6 (17 %) 6/6 (100 % 11480 (4169–15720) 43620 (37750–53440)
aCt omcB median calculated from Ct positive individuals only
bIQR = inter-quartile range
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detectable Ct infection (TF Ct+, n = 47) against TF cases
without detectable Ct infection (TF Ct-, n = 34). Results
are shown in Table 2. MiR-155, miR-150, miR-142,
miR-181b, miR-181a and miR-342 were up-regulated in
all 3 comparisons (Fig. 2). MiR-155, miR-150, miR-142,
miR-181b, miR-181a, miR-342 and miR-132 were differen-
tially expressed during current Ct infection. MiR-184 and
miR-4728 were down-regulated in TF independently of Ct
infection. MiR-184 was the only miR that was significantly
differentially expressed between uninfected normal healthy
controls (n = 77) and Ct negative TF cases (TF Ct- (n = 34),
Padj = 0.00165, FC = 0.315, data not shown). These results
are consistent with the small RNA sequencing results
(Additional file 6). MiR-147b and miR-1285, which were
up-regulated in inflammatory trachomatous scarring [15],
were not differentially expressed between TF/TI and N.
Relationship between clinical papillary inflammation and
miR expression
We investigated the relationship between clinical papil-
lary inflammation and miR expression using an ordinal
logistic regression model, which allowed us to adjust for
confounding variables and estimate the contribution of
miR expression to inflammation. Ct load was adjusted
for in order to detect miR associated with papillary
inflammation independently of Ct infection. Follicular
trachoma and papillary hypertrophy were highly collinear
(Kappa score = 5.8 x 1015, determinant of covariance
matrix = 1.92 x 10−21) therefore F score was not included
as an independent variable in this analysis as the purpose
of this model was to investigate papillary inflammation.
MiR-150, −142, −4728, −181A and -181B were up-
regulated in follicular trachoma in response to current Ct
infection (Fig. 2) and were associated with papillary in-
flammation in univariate regression analyses, but they had
Table 2 Differential expression analysis of miR by qPCR in 163 clinical samples, in three independent phenotype comparisons
TF (n = 81) v N (n = 82) TF Ct + (n = 47) V TF Ct- (n = 34) TF Ct + (n = 47) V N Ct- (n = 77)
P value Adj Pa FCb P value Adj Pa FCb P value Adj Pa FCb
miR-184 5.69 x 10−8 7.96 x 10−7 0.30 0.7571 0.7571 0.88 3.06 x 10−7 1.07 x 10−6 0.28
miR-142-5p 6.46 x 10−7 4.52 x 10−6 1.82 1.63 x 10−5 7.58 x 10−5 2.53 2.3 x 10−12 3.22 x 10−11 2.83
miR-155-5p 1.56 x 10−5 7.29 x 10−5 1.73 9.45 x 10−6 6.62 x 10−5 2.50 1.18 x 10−9 5.51 x 10−9 2.58
miR-150-5p 0.0003 0.0011 1.56 1.41 x 10−6 1.98 x 10−5 3.24 8.56 x 10−10 5.51 x 10−9 2.71
miR-181b-5p 0.0010 0.0028 1.33 0.0018 0.005 1.74 1.58 x 10−6 4.44 x 10−6 1.70
miR-342-3p 0.0041 0.0096 1.12 0.0076 0.0178 1.50 0.0001 0.0002 1.34
miR-4728-3p 0.0103 0.0207 0.75 0.0353 0.0617 0.72 0.0005 0.0008 0.65
miR-181a-5p 0.0120 0.0211 1.30 0.0151 0.0301 1.40 0.0003 0.0006 1.54
miR-375 0.0871 0.1355 0.80 0.3054 0.3887 0.81 0.0615 0.0862 0.75
miR-132-3p 0.1628 0.2279 1.09 0.0009 0.0031 1.45 0.0023 0.0035 1.27
miR-10a-5p 0.2654 0.3378 1.16 0.6729 0.7247 0.92 0.3454 0.4030 1.15
miR-146b-3p 0.5491 0.6406 0.95 0.3666 0.4277 1.15 0.9425 0.9425 1.02
miR-147b 0.6203 0.6680 1.07 0.1073 0.1669 1.44 0.2394 0.3047 1.21
miR-1285 0.8683 0.8683 0.98 0.2095 0.2933 0.83 0.4434 0.4775 0.91
Tests for difference were conducted with a T test or Wilcoxon signed rank test if data were not normally distributed
N normal, TF follicular trachoma, Ct + Ct infected, Ct- no Ct infection detected
aP adj = Adjusted P value
bFC = Fold change
Fig. 2 Patterns of differential miR expression according to clinical
phenotype. MiR expression was measured using qPCR in 163 clinical
samples. MiR labeled with double arrows had significant differences
between groups (Padj < 0.05, FC > 1.5). MiR with single arrows had
significantly different expression (Padj < 0.05) but had a FC <1.5 in
2 or 3 of the comparisons shown
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no association with papillary inflammation after adjust-
ment for Ct infection load (Additional file 7). MiR-155
(OR = 2.533 (95 % CI = 1.291–4.971), P = 0.007) and miR-
184 (OR = 0.416 (95 % CI = 0.300–0.578), P = 1.61 x 10−7)
were significantly associated with papillary inflammation
(Additional file 7). MiR-155 expression increases with pap-
illary inflammation score (Fig. 3). Significant differences in
miR-155 expression were found between P0 and P1 (Padj
= 0.03), P1 and P2/3 (Padj = 0.019) and P0 and P2/3 (Padj
= 3.6 x 10−6). MiR-184 expression decreased with papillary
inflammation score (Fig. 3). Significant differences in miR-
184 expression level were found between P0 and P1 (Padj
= 5.5 x 10−5) and between P0 and P2/3 (Padj = 4.2
x 10−5).
In separate univariate multinomial logistic regression
analyses, no associations were found between miR
expression and plasmid copy number in Ct positive indi-
viduals (data not shown). Exclusion of the two samples
with evidence of trachomatous scarring did not change
the outcomes of the differential expression or regres-
sion analyses (data not shown).
Discussion
During Ct infection of the conjunctiva in vivo 7 miR
were up-regulated. Two miR were down-regulated
during follicular trachoma in the absence of Ct. After
adjusting for the relationship between miR and Ct
infectious load, we found that miR-155 and miR-184
were independently associated with inflammation. We
also found that isolated epithelial cells in culture did
not differentially regulate miR expression in response
to Ct infection.
The Ct plasmid is a known virulence factor [35, 36]. In
a non-human primate model of trachoma A2497P- in-
fection is attenuated relative to A2497 and does not lead
to ocular pathology [24]. Attempts to elucidate the
mechanism of this attenuation are ongoing [37, 38]. In
order to understand the contribution of the epithelium,
Porcella et al. (2015) recently characterized the in vitro
transcriptome response of HeLa cells infected with
A2497 and A2497P- (at an MOI of 1) [39]. Similar tran-
scriptional profiles were induced by A2497 and A2497P-
and only modest increases in cytokine and chemokine
levels were detected in response to virulent A2497. The
authors suggested that their data supports the hypoth-
esis that Ct is a stealth pathogen [40], due to the limited
innate pro-inflammatory response induced. We did not
detect differential regulation of miR by deep sequencing
in HEp-2 or HCjE epithelial cells at 48 hpi with A2497
and A2497P- (also at an MOI of 1). This result is not
surprising in HCjE cells due to the lack of productive in-
fection achieved, however more differences might have
been expected upon productive infection of HEp-2 cells,
particularly as Porcella et al., found the largest transcrip-
tional changes occurred in response to A2497 and
A2497P- at 48hpi [39]. Our data could also be interpreted
as evidence in support of the stealth pathogen hypothesis
and suggests that Ct avoids stimulation of a miR response
in epithelial cells. Infection of HeLa cells with Salmonella
typhimurium revealed the largest changes in miR expres-
sion at 4hpi, with minimal changes detected at 24hpi
despite infecting with an MOI of 10 [41]. Therefore, it is
also possible that changes in epithelial cell miR expression
in response to Ct are limited to early time points post
infection. Limitations of this experiment were that despite
infecting with an MOI of 1 we achieved <50 % infectivity
(Additional file 1) and we sequenced three biological re-
peats per condition. The expression changes in infected
cells were therefore likely diluted by the lack of expression
change in neighboring uninfected cells and it is possible
that we did not have the statistical power to detect small
expression differences.
HEp-2 cells originated from a human laryngeal carcin-
oma but it is known that many laboratory stocks of HEp-2
cells are contaminated with HeLa cells, which are derived
from a glandular adenocarcinoma of the cervix [42]. HCjE
cells are an immortalized cell line generated from a pri-
mary conjunctival epithelial culture [43] and may repre-
sent an in vitro model that better mimics conjunctival
epithelial cells in vivo. A previous study infected HCjE and
HeLa cells with A/HAR-13 at an MOI of 0.3 and reported
that A/HAR-13 achieved higher infectious load in HCjE
cells compared to HeLa cells [44]. In contrast we were un-
able to maintain productive infections of 3 ocular strains
in HCjE cells, whereas productive infection of HEp-2 cells
with A2497 and A2497P- was achieved. These differences
Fig. 3 MiR expression correlates with clinical inflammation score.
Expression of miR-155 and miR-184 for 163 clinical samples plotted
against clinical trachoma papillary hypertrophy score. P2 and P3
categories were combined due to the low number of P3 cases.
ΔCT values were calculated by subtracting the endogenous control
(snoRNA U6) cycle threshold (CT) value from the CT value of each miR
for each individual sample. ΔCT values were inverted (40-ΔCT) in order
to show the direction of miR expression
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could reflect culture adaptation of HCjE cells [45–48]
or Ct strains [49] over time or a natural resistance of
the HCjE line to infection, perhaps due to expression of
mucins or innate antimicrobial effectors [50]. Comparison
of mock-infected HEp-2 and HCjE cell lines revealed sig-
nificant differences in miR profile. Amongst the miR that
were most significantly up-regulated in HCjE cells relative
to HEp-2 cells were several members of the miR-200
family (Additional file 4), which are known to be highly
enriched in epithelial tissues [51]. This would suggest
that HEp-2 cells present an environment to Ct that is
different to conjunctival epithelial cells and might indi-
cate that caution should be used when interpreting data
generated from these cultures in comparison to the in
vivo response.
In vivo, we found that miR-21-5p was the most abun-
dant miR in the conjunctiva of both follicular trachoma
cases and healthy control individuals (Additional file 5).
MiR-21 is transactivated by NFκB [52] and is thought
to act in a positive feedback loop in epithelial cells by
increasing NFκB activity [53]. The high expression of
miR-21 at this mucosal site may reflect NFκB stimulation
in an environment of frequent microbial exposure. We
previously found that miR-21 was abundant (Ranked 19/
503) in the conjunctiva of Gambian adults with and with-
out scarring trachoma [15]. This slight reduction in the
relative abundance of miR-21 in adults may reflect the fact
that the conjunctival microbiome of adults in The Gambia
has reduced richness and diversity of species compared to
Gambian children [54] and thus a lower level of microbial
stimulation. The reduction in abundance could also be
due to differences in microbial exposure between The
Gambia and Guinea Bissau, or the different technical
approaches used in the two studies such as small RNA
purification and quantitation.
In follicular trachoma, the miR expression signature
reflects the presence of the immune response. MiR-155,
miR-150 and miR-142 are thought to be specific for
hematopoietic cells [55] (although miR-155 expression
has been reported in epithelial cell lines [56, 57]) and
miR-155, miR-150, miR-181a, miR-146 and miR-10a
have roles in hematopoiesis (reviewed in [58]). MiR-155
in particular has wide-ranging and profound effects on
the development and function of immune cells (reviewed
in [59]). MiR-181b, miR-132, miR-10a and miR-146b
negatively regulate inflammation following TLR or NFκB
stimulation in order to prevent excessive inflammation
and pathology. A brief summary of roles that have been
described for these differentially regulated miR relating
to inflammation or fibrosis is presented in Additional file
8. The expression of these miR following stimulation of
innate pathogen recognition pathways explains their up-
regulation in response to Ct in this study. We found that
expression of miR-150, −181a, −181b, −142 and −4728
were each independently associated with increasing in-
flammatory score, however, these associations were no
longer significant after adjustment for Ct load and miR-
co-expression. MiR-155 and miR-184 alone had a strong
and direct association with papillary inflammatory score
after adjustment for these factors. Pathway analysis was
not carried out due to the relatively small and manageable
number of differentially expressed miR and the inherent
bias of current miR-based pathway analysis software [60].
A number of the miR that were differentially regulated
in Ct positive follicular trachoma cases have previously
been linked to chlamydial disease. MiR-155-5p, miR-142-
5p, miR-142-3p, miR-132-3p and miR-147-3p amongst
others were up-regulated during Cm infection of the
murine cervix in response to an attenuated strain of
Cm, relative to a virulent strain of Cm [16]. The roles
attributed to these miR in dampening inflammation
possibly explain the reduced pathology observed upon
avirulent infection. Another study found that miR-146a
was up-regulated in the murine genital tract 6 days post
infection with Cm [17]. We did not find miR-147b or
miR-1285 to be differentially expressed in Ct positive
or Ct negative follicular trachoma cases. This could reflect
differences in the inflammatory phenotype between adults
with trachomatous scarring and inflammation (TI) that
continues in the absence of Ct, compared to younger indi-
viduals with chlamydial-induced inflammation (TF and
TI). MiR-147b is also hypothesized to dampen inflamma-
tion upon LPS and TNFα stimulation [61, 62], therefore
regulation of inflammation is a key theme in both stages
of trachomatous disease. No differentially regulated miR
were detected in healthy control adults versus individuals
with scarring trachoma in our previous study; differences
were only detected in comparisons against trachomatous
scarring with inflammation [15]. These data, combined
with recent evidence that inflammation is a significant risk
factor for progressive scarring [1], support the hypothesis
that inflammatory cells are required to drive pathological
responses in the epithelium. This hypothesis perhaps also
explains the lack of miR response in our infected epithelial
cell model and suggests that inflammatory cell stimuli are
required for a miR response in the epithelium in vivo, as
might be the case for miR-184.
We found that miR-184 and miR-4728-3p were down-
regulated in follicular trachoma irrespective of Ct infec-
tion. MiR-184 was the only miR differentially expressed in
uninfected cases of follicular trachoma versus uninfected
healthy controls and was highly associated with papillary
hypertrophy score after adjustment for Ct load. MiR-184
is known to be enriched in the corneal epithelium [63]
and it is the fourth most abundant miR in control individ-
uals (F0P0C0). We previously found that miR-184 was
highly abundant (5/502) in a pool of normal healthy adults
and adults with scarring trachoma [15], suggesting tissue
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specific expression does not vary with age. A single base
substitution in the seed region of miR-184 is associated
with severe keratoconus (thinning of the cornea) [64–66].
In the cornea miR-184 is expressed in basal and supra-
basal epithelial cells [63], under which the stromal thin-
ning occurs. MiR-184 is strongly down-regulated during
acute corneal injury and expression is restored in the
re-epithelialized cornea upon healing [63]. MiR-184
also targets the Wnt receptor frizzled-7 and negatively
regulates the Wnt pathway; down-regulation of miR-
184 is associated with aberrant activation of the Wnt
pathway in ischemia-induced neovascularization of the
murine retina [67]. Delivery of miR-184 was able to inhibit
induction of the Wnt pathway, conferring miR-184 with
significant therapeutic potential. Activation of the canon-
ical Wnt pathway has previously been demonstrated in Ct
infected epithelial cells in ex-vivo fallopian tube tissue
[68], with a paracrine effect that resulted in a loss of epi-
thelial homeostasis. Altogether, these data suggest that a
down-regulation of miR-184 in follicular trachoma once
Ct has been cleared reflects a prolonged wound healing
process and activation of the Wnt pathway, possibly
contributing to pathology. Prolonged down-regulation
of miR-184 may also contribute to epithelial thinning,
which is observed in trachoma, potentially predisposing
individuals more to subsequent bacterial infections. Fu-
ture work should focus on the expression of miR-184
and activity of the Wnt pathway in a longitudinal set of
clinical samples to determine the contribution of this
pathway to the development of trachomatous pathology.
There was considerable variation in load between the
Ct infected follicular trachoma cases in this study. Con-
junctival cells obtained by a swab are expected to be
heterogeneous in the number of infected and uninfected
epithelial cells and the number of immune cells. The
majority of epithelial cells are likely to be uninfected;
reducing our power to detect miR expression differences
in infected epithelial cells and perhaps explaining why
the majority of differentially regulated miR detected in
vivo were hematopoietic cell-associated. This heterogen-
eity is a caveat of using clinical samples. In order to inves-
tigate the host miR response of Ct infected epithelial cells
in vivo infected cells could be isolated and subjected to
single cell miRNA expression analysis [69].
Conclusions
We identified 7 miR that were up-regulated by current
chlamydial infection during follicular trachoma. MiR-184
and miR-4728 were down-regulated during follicular
trachoma in the absence of Ct. MiR-155 and miR-184
were inversely correlated with pathological inflammation,
which is known to be a major risk factor for scarring
trachoma. Future studies using more sophisticated in vitro
models (such as co-culture) involving miR silencing or
overexpression coupled with longitudinal studies in vivo
will help develop our understanding of the functions of
these miR, their use as predictive biomarkers of scarring
trachoma and their potential as novel treatment targets.
Additional files
Additional file 1: Chlamydial infection of HEp-2 and HCjE cell lines
with three ocular Ct strains. HEp-2 cell monolayers infected with Ct
strains A2497 (A), A2497P- (B) and A/HAR-13 (C), and HCjE cell monolayers
infected with Ct strains A2497 (D), A2497P- (E) and A/HAR-13 (F) at 48 hpi.
Cell nuclei are stained with DAPI (blue) and Ct inclusions are stained with
anti-C. trachomatis MOMP antibody (FITC (green)). Cells were infected with
an MOI of 1 and viewed at 40X magnification. Representative photographs
were taken from one of three replicates for each condition. (PDF 770 kb)
Additional file 2: Differential expression analysis of miR from
A2497 and A2497P- infected HEp-2 cells. Results of DESeq differential
expression analysis of sequencing read count data for uninfected HEp-2
cells versus HEp-2 cells infected with A2497 and A2497P- strains of
Chlamydia trachomatis at 48hpi. MiR with an average read count <5
were excluded. Three biological replicates of each condition were sequenced
and analyzed. MRC = Mean read count, −VE = mock-infected cells.
(XLS 141 kb)
Additional file 3: Differential expression analysis of miR from
A2497 and A2497P- infected HCjE cells. Results of DESeq differential
expression analysis of sequencing read count data for uninfected HCjE
cells versus HCjE cells infected with A2497 and A2497P- strains of
Chlamydia trachomatis at 48hpi. MiR with an average read count <5
were excluded. Three biological replicates of each condition were
sequenced and analyzed. MRC =Mean read count, −VE =mock-infected
cells. (XLS 137 kb)
Additional file 4: Differential expression analysis of miR from
uninfected HCjE versus HEp-2 cells. Results of DESeq differential
expression analysis of sequencing read count data for uninfected HEp-2 cells
versus uninfected HCjE cells at 48hpi. MiR with an average read count <5
were excluded. Three biological replicates of each condition were sequenced
and analyzed. MRC = Mean read count, −VE = mock-infected cells.
(XLS 102 kb)
Additional file 5: Relative abundance of miR in the conjunctiva of
cases of follicular trachoma (TF) and controls (N). MiR with a mean
read count in TF cases or controls < 5 were excluded. MiR were ranked
by mean read count across all five samples of each phenotype group.
(PDF 678 kb)
Additional file 6: Differential expression analysis of miR from
individuals with follicular trachoma versus healthy controls. Results
of DESeq differential expression analysis of sequencing read count data
for normal healthy controls (N) versus cases of follicular trachoma (TF)
with current Chlamydia trachomatis (Ct) infection (five samples of each).
MiR with an average read count <5 were excluded. MRC =Mean read
count. (XLS 73 kb)
Additional file 7: Multivariable regression model of the
contribution of miR expression to clinical papillary hypertrophy
score. Collapsed papillary hypertrophy score (P0, P1 or P2/3, as defined
by the WHO 1981 FPC scoring system) was used as an ordinal outcome
variable to define trachomatous inflammation in 163 clinical samples.
Age, gender, Ct load and inverted ΔCT values (40-ΔCT) of miR are
included as independent variables. Model AIC (Akaike information
criterion) is 227.3725. aOR = Odds ratio, bCI = confidence intervals, cCt load
is defined as log-(e) omcB copies/swab. (PDF 59 kb)
Additional file 8: Focused list of published roles for miR that are
differentially expressed in follicular trachoma that relate to
inflammation or fibrosis. (PDF 59 kb)
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ΔCT: delta cycle threshold value; CI: confidence interval; Ct: Chlamydia
trachomatis; F score: follicle score; hpi: hours post-infection; miR: microRNA;
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